Abstract
Epithelial-mesenchymal transition (EMT) is a developmental process that converts epithelial cells into migratory and invasive cells. This process also plays an important role in cancer progression and metastasis by enabling tumor cells to leave primary sites. EMT is regulated by complex transcription networks and post-transcriptional modulators. MicroRNAs are single-stranded non-coding RNAs that represent a novel class of gene regulators. It has been shown that microRNAs are critical regulators of EMT process. The molecular mechanisms of EMT modulation by microRNAs include the suppression of transcription factors that directly regulate EMT and the down-regulation of cellular genes and pathways that are indirectly involved in EMT process. The expressions of microRNAs that control EMT process are dysregulated in cancer. In this review, we summarize the recent progress of microRNAs in EMT regulation.
Keywords: Cancer, epithelial-mesenchymal transition, microRNA, migration, non-coding RNA, transcription.
Current Cancer Drug Targets
Title:Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer
Volume: 13 Issue: 9
Author(s): Jinchun Yan, Kiranmai Gumireddy, Anping Li and Qihong Huang
Affiliation:
Keywords: Cancer, epithelial-mesenchymal transition, microRNA, migration, non-coding RNA, transcription.
Abstract: Epithelial-mesenchymal transition (EMT) is a developmental process that converts epithelial cells into migratory and invasive cells. This process also plays an important role in cancer progression and metastasis by enabling tumor cells to leave primary sites. EMT is regulated by complex transcription networks and post-transcriptional modulators. MicroRNAs are single-stranded non-coding RNAs that represent a novel class of gene regulators. It has been shown that microRNAs are critical regulators of EMT process. The molecular mechanisms of EMT modulation by microRNAs include the suppression of transcription factors that directly regulate EMT and the down-regulation of cellular genes and pathways that are indirectly involved in EMT process. The expressions of microRNAs that control EMT process are dysregulated in cancer. In this review, we summarize the recent progress of microRNAs in EMT regulation.
Export Options
About this article
Cite this article as:
Yan Jinchun, Gumireddy Kiranmai, Li Anping and Huang Qihong, Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer, Current Cancer Drug Targets 2013; 13 (9) . https://dx.doi.org/10.2174/15680096113136660098
DOI https://dx.doi.org/10.2174/15680096113136660098 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Establishing Maternal Tolerance: The Role of Regulatory T Cells (Tregs) in Pregnancy and Pathophysiology of Preeclampsia
Current Women`s Health Reviews Menstrual and Reproductive Outcomes Following Uterine Artery Fibroid Embolisation: A Literature Review
Current Women`s Health Reviews Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
Current Pharmaceutical Design The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Non-Steroidal Targets in the Diagnosis and Treatment of Endometriosis
Current Medicinal Chemistry Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets Treatment of Uterine Carcinomas
Current Cancer Therapy Reviews Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Embryonic Morphogenetic Field Induces Phenotypic Reversion in Cancer Cells. Review Article
Current Pharmaceutical Biotechnology New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Genetic Instability Influences Drug Response in Cancer Cells
Current Drug Targets Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening